ALDH3A1 and pancreatic adenocarcinoma: Yang et al. showed that ALDH3A1 is a key metabolic marker upregulated in pancreatic adenocarcinoma patients with new-onset diabetes, contributing to tumor progression, immune suppression, and poor prognosis [41].